Sophoricoside from Sophora japonica ameliorates allergic asthma by preventing mast cell activation and CD4+ T cell differentiation in ovalbumin-induced mice - 19/12/20
pages | 10 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | The mature seeds of S. japonica contain a large amount of sophoricoside, compared to leaves, stems and roots. |
• | Sophoricoside ameliorates allergic asthma by suppressing airway inflammation in OVA-induced mice. |
• | Sophoricoside decreases secretion of immunoglobulins in serum of OVA-induced mice. |
• | Sophoricoside decreases release of histamine and arachidonic acid metabolites via inhibition of mast cell activation. |
• | Sophoricoside suppresses CD4+ T cell differentiation into Th cell subets. |
Abstract |
Asthma is a chronic inflammatory lung disorder with continuously increasing prevalence worldwide. Novel strategies are needed to prevent or improve asthma. The aim of this study was to investigate the effects of sophoricoside from Sophora japonica on allergic asthma. The mature seeds of S. japonica contain a large amount of sophoricoside. Sophoricoside reduced allergic and asthmatic symptoms by suppressing airway inflammation and antibody-antigen reaction in mouse models. In particular, sophoricoside suppressed immune cell recruitment into the airway lumens of the lungs and production of pro-inflammatory cytokines in the bronchoalveolar lavage fluid (BALF) of ovalbumin (OVA)-induced mice. It also decreased the amounts of histamine and arachidonic acid metabolites released in OVA-induced mice and antibody-antigen stimulated mast cells. In addition, sophoricoside decreased differentiation of naïve CD4+ T cells into T helper type 1 (Th1), Th2, and Th17 cells. Overall, we demonstrated that sophoricoside improved allergic asthma by suppressing mast cell activation and CD4+ T cell differentiation.
Le texte complet de cet article est disponible en PDF.Keywords : Airway inflammation, Allergic asthma, CD4+T cell, Mast cell, Ovalbumin, Sophoricoside
Plan
Vol 133
Article 111029- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?